Bio-fd&c KRX:251120KOSDAQ
바이오에프디엔씨 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked4since Sep 11
In Q2 2026, Bio-fd&c reported revenue of ₩5.4bn, up 14.5% year on year, and operating profit of ₩2.1bn. Bio-fd&c (바이오에프디엔씨) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals Op. margin 20%+ Share pledge Screener
Bio-fd&c quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩5.4bn | +14.5% | ₩2.1bn margin 39.2% | ₩2.0bn |
| Q1 2026 | ₩4.0bn | -7.5% | ₩1.0bn margin 25.7% | ₩1.2bn |
| Q4 2025 derived | ₩5.1bn | +7.7% | ₩1.3bn margin 25.0% | ₩1.3bn |
| Q3 2025 | ₩5.1bn | +41.0% | ₩1.7bn margin 33.4% | ₩1.9bn |
| Q2 2025 | ₩4.7bn | +19.1% | ₩1.8bn margin 39.4% | ₩1.8bn |
| Q1 2025 | ₩4.3bn | +13.8% | ₩1.4bn margin 33.3% | ₩1.6bn |
| Q4 2024 derived | ₩4.7bn | -0.0% | ₩1.6bn margin 33.6% | ₩1.8bn |
| Q3 2024 | ₩3.6bn | -8.4% | ₩1.1bn margin 29.6% | ₩1.1bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Bio-fd&c top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.